-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
WCLC News
-
Interim Analysis Shows IDeate-Lung01 Study Met Primary Endpoint
Dr. Charles Rudin says early data look promising for I-DXd in patients with ES-SCLC.
-
Hands-On Genomics Workshop Enables Participants to Integrate Genomic Testing Into Patient Care
Drs. Ramaswamy Govindan, Richard Haspel, and Aparna Sharma took the audience on a guided tour of pragmatic lung cancer genomics.
-
Save the Date: Planning Begins for the 2025 World Conference on Lung Cancer
Drs. Isabelle Opitz, Umberto Malapelle, Noemi Reguart, and Jarushka Naidoo will co-chair the event, which will return to Barcelona next September.
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
During the session, Dr. Hisao Asamura reviewed the criteria changes in the new 9th edition of the TNM classification recommendations.
-
Novel, Targeted TKI Brings Hope to a Rare, Clinically Challenging Disease
Dr. Gerrina Ruiter says zongertinib shows encouraging preliminary findings in patients with HER2-mutated NSCLC.
-
Study Results Support Continued Research of HER2-Targeted TKI
Dr. Xiuning Le presented data from a first-in-human trial that show a rapid, durable response in HER2-mutated NSCLC.
-
Study Shows AI-Based Method Predicts Gene Mutation, Distribution in a More Timely, Accurate, and Economical Way Compared to NGS
Dr. Shan Xiong says the technology achieved robust and superior predictive performance across cancer genes of diverse types and across racial backgrounds.
-
IASLC Recognizes Champions of Lung Cancer Advocacy and Research with STARS Scholar Program
The IASLC’s Supportive Training for Advocates on Research and Science Program Provides Tools, Resources, and Education to Aspiring Patient Research Advocates.
-
IASLC Looks Back at 50 Years of Growth, Collaboration, and Progress in Lung Cancer
A special plenary at WCLC 2024 recognized a half-century of advances in thoracic oncology while reflecting on how far the IASLC has come since its first meeting.
-
Study Shows Patients at Lowest Risk May Benefit from Longer Intervals Between Lung Cancer Screening
Dr. Annette McWilliams says the PanCan nodule management protocol demonstrates potential to streamline lung cancer screening and management processes.